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Cell cycle aberrations and neurodegeneration
The cell cycle is a highly regulated and fundamental cel-
lular process that involves complex feedback regulation of
many proteins, and any compromise to its integrity elicits
dire consequences for the cell. For example, in neurode-
generative diseases such as Alzheimer disease (AD), evi-
dence for abnormal cell cycle re-entry precedes other
hallmarks of disease and as such, implicates cell cycle
aberrations in the aetiology of AD. The mechanism(s) for
cell cycle re-entry in AD, however, remain unclear.
Current theory suggests it to be part of a combination of
early events that together elicit the degenerative pathology
and cognitive phenotype consistent with the disease. We
propose a ‘Two-Hit Hypothesis’ that highlights the con-
certed interaction between cell cycle alterations and oxi-
dative stress that combine to produce neurodegeneration.
Here, we review the evidence implicating cell cycle mecha-
nisms in AD and how such changes, especially in com-
bination with oxidative stress, would lead to a cascade
of events leading to disease. Based on this concept, we
propose new opportunities for disease treatment.
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Introduction
The cell cycle consists of elaborate feedback mechanisms
and regulatory checkpoints that are typically divided into
four phases: S-phase, during which DNA replication
occurs, M-phase, where cell division, or mitosis, takes
place, and the gap phases that separate the two; G1 and G2,
respectively. Additionally, quiescent cells, such as many of
the neurones in the adult hippocampus, exist in a non-
dividing, silent phase known as G0. Once in this phase,
cells are deemed terminally differentiated, meaning they
are not capable of re-entering the cell cycle [1]. It is in
this capacity that vulnerable neurones are affected. As
increasing evidence indicates, cells that exist in G0, and
thus are no longer mitotically active, become wrongly
reactivated in Alzheimer disease (AD) and other neurode-
generative diseases, and are forced through a cell cycle
that they are no longer capable of completing [2–5]. That
is, re-entrant cells that proceed past late G1, some even
entering and completing S-phase, cannot return to G0.
Moreover, for reasons not completely understood, these
already differentiated cells cannot undergo mitosis, and,
because of limited options, induced their own deaths via
apoptotic pathways [6,7]. As this phenotype precedes
much of the other associated markers of neurodegenera-
tion in AD [8], it is of increasing relevance to the field and
merits further investigation.
Cell cycle protein regulation
Vital to the cycle, and thus to the proliferation of the cell,
are the set of proteins generally associated with guiding
the cell from one phase to the next. These proteins, the
cyclins and the associated cyclin-dependant kinases
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(cdks), fluctuate in their expression and activity as the cell
transitions from S-phase to M-phase [9,10]. In particular,
the expression/activation of cyclin D/cdk4,6 complex,
which is triggered by the presence of mitotic growth
factors, control the re-entry of resting (G0) cells into the G1
phase of cell cycle [11]. The G1/S transition, then, is con-
trolled by the activation of the cyclin E/cdk2 complex [11]
such that the absence of cyclin E and/or the inhibition of
the cyclin E/cdk2 complex by p21, p27 and p53 causes the
cell cycle to be arrested at the G1 checkpoint. The subse-
quent fate of the G1-arrested cells depends on the presence
or absence of cyclin A [9] such that, in the absence of
cyclin A, the cells return to G0 and re-differentiate.
However, if allowed to proceed, in the presence of cyclin A,
the cells are committed to division, lack the ability to
re-differentiate and, if unable to complete the cell cycle, die
via an apoptotic pathway [6]. Therefore, once beyond late
G1, when cyclin A is expressed, arrest will lead to cell
death.
The regulation of the cyclin–cdk complexes is achieved
through cyclic proteolysis [12]. In a functioning cell, the
mitotic cycle progresses as the appropriate cyclins are
expressed while all others are inhibited. Furthermore, to
enable the completion of one phase and the correspond-
ing transition to another, the controlled proteolysis of the
former’s cyclins effectively down-regulates the events of
the first phase such that the next phase can proceed
(through the subsequent up-regulation of its cyclins). As
we shall see, however, despite the pivotal role of proteolysis
in cell cycle regulation, the re-entrant phenotype charac-
teristic of neurodegenerative disorders like AD is not the
result of its reduced activity. Rather, it is a triggered depar-
ture from G0 to G1 (via cyclin D/cdk4, 6) that initiates the
tragic demise of the cell [13–15].
Alzheimer disease and the cell cycle:
overlapping phenotypes
Alzheimer disease is characterized by neurodegeneration
and cognitive impairment and is the leading cause of
senile dementia in the USA, affecting 15% of people over
65 years and almost 50% of those over 85 years [16].
Although the precise molecular mechanisms behind its
pathogenesis are not fully understood, several key ele-
ments to the disease are noteworthy. Specifically, the
hallmark features of AD, neurofibrillary tangles and
amyloid-b (Ab) plaques, while not the sole proprietors of
neurodegeneration, are crucial to its development.
Amyloid-b is the major component of senile plaques
characteristic of AD and is derived from its precursor,
amyloid-b protein precursor (AbPP), which is encoded on
chromosome 21 [17]. Its importance in disease is attested
to the fact that mutations in the AbPP gene are directly
linked to the onset of familial AD [18]. While recent evi-
dence indicates the initial role of Ab to be one of oxidative
protection [19], its accumulation in neuronal tissue is cer-
tainly detrimental to cell functioning and survival. Specifi-
cally, Ab-senile plaques elicit responses from surrounding
microglial and astrocytic cells [20,21] and may ultimately
ensure neuronal cell death through increased oxidative
damage and further self-aggregation [22]. Interestingly,
studies report AbPP to be up-regulated by mitogenic
stimulation and that AbPP metabolism is controlled by
cell cycle-dependant changes [23–25]. Even more, Ab
itself has been identified as mitogenic in vitro [23,24];
events of the cell cycle and their malfunctions have there-
fore been implicated in AD neurodegeneration.
Similarly, the major protein component of neuro-
fibrillary tangles, a hyperphosphorylated form of the
microtubule-associated protein tau [26,27], produces
neuronal dysfunction in AD through microtubule desta-
bilization. Notably, this hyperphosphorylated tau pathol-
ogy is present in normal, mitotically active cells and has
been linked to the activity of cdks [28,29]; once again, cell
cycle mechanisms are indirectly involved in the process of
AD onset and development.
Oxidative stress, another crucial aspect of the neurode-
generation associated with AD, has become increasingly
significant in the pathogenesis of the disease over the past
few years and has also been identified as concordant with
markers of the cell cycle and its aberrations [3]. While its
exact origins are not certain, it has been demonstrated to
be one of the primary role-players in the onset of AD and
in its development. That is, markers of oxidative stress,
such as 8-hydroxyguanosine, precede general signs of AD
in immunohistochemically stained neurones by decades
[3,30]. Furthermore, Ab, which has been revealed to be a
high-valence metal chelator [31,32] and effective antioxi-
dant in its soluble, non-aggregated form [31,33], may ini-
tially exist in the brain as a respondent mechanism for
oxidative stress relief. Once oxidized, however, Ab becomes
insoluble and aggregates to impose the cellular burden for
which it is known.
Importantly, though, recent research indicates a direct
and reciprocally causal relationship between oxidative
stress and cell cycle abnormalities [3], and it is this rela-
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tionship that merits further investigation. In particular, a
‘two-hit’ hypothesis has been suggested whereby AD neu-
rodegeneration becomes manifest as a result of both oxi-
dative stress and cell cycle malfunctioning [3,34,35]. The
disease pathogenesis, instigated by either one of the two
aforementioned factors, develops as a combined process.
For instance, oxidative stress, as one factor, damages neu-
rones to eventually elicit the other factor, in this case cell
cycle dysfunction. The effects of these two ‘hits’ ultimately
initiate a detrimental cycle of oxidative stress, inflamma-
tion, Ab aggregation, mitotic dysfunction and cell death
that is responsible for disease. As such, cell cycle abnor-
malities offer a target for finding new therapeutic possibili-
ties for patients.
Cell cycle malfunctions in Alzheimer disease
Several lines of evidence indicate the predominant role
of cell cycle malfunctioning in the pathogenesis of AD.
First, AD neurones exhibit significantly elevated levels of
cell cycle markers representative of a departure from
quiescence as compared with age-matched controls
[3,13,14,36–38]. In particular, the presence of cyclin D,
cdk4 and Ki67 in diseased neurones as well as cyclin
E/cdk4 complex elevations confirm that the cells have
indeed passed the G1 phase and are no longer in G0
[3,13,36]. Moreover, it seems that these indicators of cell
cycle activation are located in the cell cytoplasm in AD
vulnerable neurones rather than within the nucleus
where they normally act [37,39,40]. A successful dupli-
cation of DNA in some AD neurones, as well as the pres-
ence of S-phase proteins like pmcm2 [41], even suggests a
transition through the S-phase, and the appearance of
aneuploidy strengthens this possibility [42].
Premature chromosome separation (PCS), a phenom-
enon that is responsible for diseases such as Robert’s
syndrome and various cancers, and whose presence
indicates a successful replication of DNA, as well as an
abnormal mitotic phenotype presents convincing evi-
dence for cell cycle re-entry in AD neurones [43]. Studies
specifically demonstrate PCS appearing directly after
DNA replication in G2 phase of the cell cycle, and evi-
dence points to malfunctions of X-chromosome replica-
tion as being particularly prevalent: the presence of PCS
in women statistically exceeds that in men [44], and
women who are at risk for aneuploidy offspring (i.e.
Down’s syndrome) exhibit twice the demonstrated
relationship between loss of replication control, cen-
tromere dysfunction and predisposition to non-
disjunction, possibly contributing to AD pathogenesis in
these individuals [45,46]. The regulation of centromere
and chromosome separation is orchestrated by the
multitude of cell cycle proteins, such as cyclins and
cyclin-dependant kinases, and thus the dysfunction of
this process is another potential consequence of dis-
turbed cellular cycling.
As previously mentioned, the presence of aberrant cell
cycle makers in AD neurones significantly precedes the
appearance of gross indicators of AD, and mitotic dys-
function is therefore implicated in disease onset and early
development or predisposition. As such, there are several
possible factors that might elicit vulnerable neurones to
inappropriately re-enter the cell cycle. Mitotic signalling,
in particular, seems to be partly responsible, as reports
have identified an altered expression of the cell cycle-
mediating G-protein, Ras, in AD-affected cells [2,47].
This protein is especially involved in the cellular transi-
tion from G0 to G1 phase through its interactions with
cyclin D1 [10], and its downstream mediators, MAPK,
Raf and MEK1/2, have all been identified as activated in
AD neurones as compared with controls.
Some of the key genes already implicated in the patho-
genesis of AD may contribute to aberrant cell cycle
re-entry and consequent neurodegeneration. In particu-
lar, three genes, AbPP, and the homologous genes Pres-
enilin 1 and Presenilin 2 (PS1/2), are associated with
early onset AD [48,49] and have been implicated as the
role-players in the cell cycle and cell cycle control. AbPP,
a single-pass, transmembrane protein, is proteolytically
cleaved to yield Ab peptide; both proteins have been iden-
tified as mitogenic in vitro [23,24]. Particularly interest-
ing is that AbPP-BP1, an adaptor protein involved in the
cleavage of AbPP, is a cell cycle protein that regulates
mitotic transition from S to M-phase. An overexpres-
sion of AbPP-BP1 would therefore push neurones into
the S-phase and cause DNA replication and expression
of corresponding cell cycle markers cdc2/cyclin B
[4,10,50]. As these phenotypes are evident in AD
neurodegeneration, it is possible that AbPP-BP1-
induced cell cycle re-entry could be at least partially
responsible.
Likewise, the PS1/2 genes, approximately 67% homolo-
gous, are responsible for the proteolytic cleavage of AbPP
[10] and are thus also implicated in cell cycle control, as
well as in the pathogenesis of AD. In the former scenario,
the homologous genes have been associated with the
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centromere and centrosome of dividing cells [51], thus
providing another link to mitogenic alterations in
neurodegeneration, aside from the obvious interactions
with AbPP. In particular, an overexpression of PS1 and
PS2 in transfected HeLa cells resulted in G1 phase arrest in
the cell cycle [10,52,53], while its deficiency produced
accelerated transgression from G1 to S-phase [54]. As the
PS1/2 genes are pivotal in the onset of some familial onset
AD, a link between cell cycle aberration and neurodegen-
eration is possible.
Cell cycle aberrations contribute to
neurodegeneration in AD
Regardless of the cause of cell cycle abnormalities evident
in AD, the consequences are the same. That is, inappropri-
ate re-entry into the cell cycle by already differentiated,
adult neurones results in cellular dysfunction, premature
cell death, and thus neurodegeneration [3] (Figure 1).
Because the cell cycle integrates such a wide variety of
cyclins and cyclin-dependant kinases, all with complex
interactions within the cell that are vital for cell prolifera-
tion and survival, any alterations in their expression,
functioning or control is likely to be damaging.
Evidence indicates the re-entrant phenotype as one of
inevitable cell death, as cells that inappropriately initiate
mitosis fail to complete the M-phase, and thus die [3,10].
Specifically, despite all of the cell cycle markers that have
been localized within adult neurones in AD brains, there
has been no indication of an entry into or a completion
of M-phase. While many cells do exhibit DNA replica-
tion, chromosome maintenance protein expression and
binucleation events [55] (and thus a completion or at
least entrance into S-phase [41,56]), and some cells have
been observed in G2-phase [37,38], no study demon-
strates an entrance into or completion of M-phase [40]. It
seems as though these cells encounter a ‘mitotic catastro-
phe’ during which they are unable to complete the cell
cycle as a result of inadequate control. Unfortunately,
because they have already crossed the point of no return
in mitosis (i.e. G1-phase/S-phase), affected neurones ulti-
mately die.
It is of interest that the molecular mechanisms behind
cell death associated with mitotic re-entry seem to be
closely involved with oxidative stress. As both phenomena
are manifest early in the pathogenesis of AD, and as
advanced cases of AD exhibit markers of both [3], it seems
likely that there is a relationship between the two pro-
cesses in neurodegeneration. The ‘two-hit’ hypothesis pro-
poses this case: either of the two cellular insults (oxidative
stress or mitotic dysfunction) can initiate a combined
process such that the combination produces cellular
dysfunction and ultimately death [3]. In particular, the
process involves the initial presence of a ‘steady state’ (fol-
lowing the expression of either oxidative stress or mitotic
malfunction) and the corresponding compensatory
adaptations that ultimately hinder overall cellular func-
tioning [3].
In regard to mitotic abnormalities, studies with several
transgenic mouse models indicate that neuronal cell cycle
Figure 1. Terminally differentiated neurones may re-enter the cell cycle via dysregulation induced by mutations in key genes (i.e. amyloid-b
protein precursor or Presenilin 1 and Presenilin 2) or alternatively as a consequence of the vulnerability created by an oxidative steady state.
Once in the cycle, the cells eventually die via apoptosis as they are unable to enter and complete M-phase (some even arresting after
G1-phase completion). Neurodegeneration is thus the result, as shown.
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re-entry (due to mutations in AbPP, PS1 or PS2) precedes
amyloid deposition, and thus full AD pathogenesis, by
several months and occurs in an anatomical pattern that
resembles the neuronal vulnerability seen in AD [3,57].
Although these mice demonstrate significant cell cycle
re-entry at as early as 6 months of age, they maintained
cognition and cellular functioning at a near-normal level
for long periods of time [3]. Such mutant mice demon-
strate a ‘mitotic steady state’ phenotype that eventually
elicits further insult in the form of a ‘second hit’ of oxida-
tive stress.
In the much more prevalent, sporadic form of AD (or
late-onset AD), an ‘oxidative imbalance steady state’ has
been demonstrated that predisposes affected neurones to
develop cell cycle abnormalities as a ‘second hit’ [3].
Although neurones are capable of compensating for acute
levels of oxidative stress in the brain, widespread accumu-
lation of reactive oxidative species eventually requires
cellular adaptations that describe a state of oxidative
imbalance [58,59]. While these compensations might
enable neurones to survive for decades under severe oxi-
dative stress [60], their eventual accumulation leads to
secondary cell cycle abnormalities, which lead ultimately
to death.
Conclusions
Alterations in cell cycle control system are likely to play a
role in neurodegeneration. While the precise origins of
such mitotic dysfunction are not fully understood, oxida-
tive defects do provide pathways from which altered cell
cycle control could arise. In AD, a complex and reciprocal
interaction between oxidative stress and cell cycle re-entry
seems likely. Cell cycle dysfunction is a factor in the neu-
ronal dysfunction in neurodegenerative disease with pos-
sible therapeutic avenues for disease control.
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